[Form 3] Rafael Holdings, Inc. Initial Statement of Beneficial Ownership
Joshua M. Fine, Chief Operations Officer of Rafael Holdings, Inc. (RFL), filed a Form 3 reporting ownership following an event dated 08/04/2025. He holds 9,380 Class B common shares (held jointly with his wife) and stock options totaling 137,881 shares from five grants exercisable 2021–2025 with exercise prices ranging from $1.00 to $21.16. The shares and options were received or converted in connection with the business combination with Cyclo Therapeutics on March 25, 2025.
Joshua M. Fine, Chief Operations Officer di Rafael Holdings, Inc. (RFL), ha presentato un Form 3 per segnalare la propria partecipazione in relazione a un evento datato 08/04/2025. Detiene 9,380 azioni ordinarie di classe B (in comunione con la moglie) e stock option per un totale di 137,881 azioni derivanti da cinque assegnazioni esercitabili tra il 2021 e il 2025, con prezzi di esercizio compresi tra $1.00 e $21.16. Le azioni e le opzioni sono state ricevute o convertite in relazione alla combinazione aziendale con Cyclo Therapeutics il 25 marzo 2025.
Joshua M. Fine, Director de Operaciones (Chief Operations Officer) de Rafael Holdings, Inc. (RFL), presentó un Formulario 3 notificando su participación tras un hecho fechado el 08/04/2025. Posee 9,380 acciones ordinarias Clase B (en copropiedad con su esposa) y opciones sobre acciones por un total de 137,881 acciones procedentes de cinco concesiones ejercitables entre 2021 y 2025, con precios de ejercicio que van de $1.00 a $21.16. Las acciones y las opciones fueron recibidas o convertidas en relación con la combinación empresarial con Cyclo Therapeutics el 25 de marzo de 2025.
Joshua M. Fine는 Rafael Holdings, Inc. (RFL)의 최고운영책임자(Chief Operations Officer)로서 08/04/2025자 사건과 관련해 소유를 신고하는 Form 3를 제출했습니다. 그는 배우자와 공동 보유 중인 9,380주의 클래스 B 보통주와 2021년부터 2025년까지 행사 가능한 다섯 건의 부여에서 나온 총 137,881주의 스톡옵션을 보유하고 있으며, 행사가격은 $1.00~$21.16입니다. 해당 주식과 옵션은 2025년 3월 25일 Cyclo Therapeutics와의 기업 결합과 관련하여 수령되거나 전환되었습니다.
Joshua M. Fine, Chief Operations Officer de Rafael Holdings, Inc. (RFL), a déposé un formulaire 3 déclarant sa participation suite à un événement daté du 08/04/2025. Il détient 9 380 actions ordinaires de classe B (en indivision avec son épouse) et des options d'achat totalisant 137 881 actions issues de cinq attributions exerçables entre 2021 et 2025, avec des prix d'exercice allant de 1,00 $ à 21,16 $. Les actions et options ont été reçues ou converties dans le cadre de la fusion avec Cyclo Therapeutics le 25 mars 2025.
Joshua M. Fine, Chief Operations Officer von Rafael Holdings, Inc. (RFL), reichte ein Form 3 ein, um seinen Besitz im Zusammenhang mit einem Ereignis vom 08/04/2025 zu melden. Er hält 9.380 Class‑B‑Stammaktien (gemeinsam mit seiner Ehefrau) und Aktienoptionen im Gesamtumfang von 137.881 Aktien aus fünf Zuteilungen, die in den Jahren 2021–2025 ausübbar sind, mit Ausübungspreisen zwischen $1.00 und $21.16. Die Aktien und Optionen wurden im Zusammenhang mit der Unternehmenszusammenführung mit Cyclo Therapeutics am 25. März 2025 erhalten oder umgewandelt.
- Form 3 disclosure explicitly reports 9,380 Class B shares and detailed option grants, improving transparency for investors.
- Holdings were received/converted in connection with the business combination with Cyclo Therapeutics on March 25, 2025, which the filing documents.
- None.
Insights
TL;DR Routine insider disclosure: COO reports direct holdings of shares and multiple option grants tied to the Cyclo combination.
The Form 3 provides a clear, itemized record of Mr. Fine's direct beneficial ownership: 9,380 Class B shares and five option grants totaling 137,881 underlying shares with exercise prices from $1.00 to $21.16. The disclosure is standard post-transaction reporting and allows investors to quantify insider exposure and potential future dilution from exercisable options.
TL;DR Filing documents insider holdings after a merger; disclosure appears complete and timely for a Form 3.
The filing identifies Mr. Fine as the Chief Operations Officer and reports both direct share ownership (jointly held) and direct option holdings. It states the provenance of the securities as conversion/receipt in the business combination with Cyclo on March 25, 2025. The form is signed by a power of attorney on 08/11/2025, consistent with routine administrative handling of insider filings.
Joshua M. Fine, Chief Operations Officer di Rafael Holdings, Inc. (RFL), ha presentato un Form 3 per segnalare la propria partecipazione in relazione a un evento datato 08/04/2025. Detiene 9,380 azioni ordinarie di classe B (in comunione con la moglie) e stock option per un totale di 137,881 azioni derivanti da cinque assegnazioni esercitabili tra il 2021 e il 2025, con prezzi di esercizio compresi tra $1.00 e $21.16. Le azioni e le opzioni sono state ricevute o convertite in relazione alla combinazione aziendale con Cyclo Therapeutics il 25 marzo 2025.
Joshua M. Fine, Director de Operaciones (Chief Operations Officer) de Rafael Holdings, Inc. (RFL), presentó un Formulario 3 notificando su participación tras un hecho fechado el 08/04/2025. Posee 9,380 acciones ordinarias Clase B (en copropiedad con su esposa) y opciones sobre acciones por un total de 137,881 acciones procedentes de cinco concesiones ejercitables entre 2021 y 2025, con precios de ejercicio que van de $1.00 a $21.16. Las acciones y las opciones fueron recibidas o convertidas en relación con la combinación empresarial con Cyclo Therapeutics el 25 de marzo de 2025.
Joshua M. Fine는 Rafael Holdings, Inc. (RFL)의 최고운영책임자(Chief Operations Officer)로서 08/04/2025자 사건과 관련해 소유를 신고하는 Form 3를 제출했습니다. 그는 배우자와 공동 보유 중인 9,380주의 클래스 B 보통주와 2021년부터 2025년까지 행사 가능한 다섯 건의 부여에서 나온 총 137,881주의 스톡옵션을 보유하고 있으며, 행사가격은 $1.00~$21.16입니다. 해당 주식과 옵션은 2025년 3월 25일 Cyclo Therapeutics와의 기업 결합과 관련하여 수령되거나 전환되었습니다.
Joshua M. Fine, Chief Operations Officer de Rafael Holdings, Inc. (RFL), a déposé un formulaire 3 déclarant sa participation suite à un événement daté du 08/04/2025. Il détient 9 380 actions ordinaires de classe B (en indivision avec son épouse) et des options d'achat totalisant 137 881 actions issues de cinq attributions exerçables entre 2021 et 2025, avec des prix d'exercice allant de 1,00 $ à 21,16 $. Les actions et options ont été reçues ou converties dans le cadre de la fusion avec Cyclo Therapeutics le 25 mars 2025.
Joshua M. Fine, Chief Operations Officer von Rafael Holdings, Inc. (RFL), reichte ein Form 3 ein, um seinen Besitz im Zusammenhang mit einem Ereignis vom 08/04/2025 zu melden. Er hält 9.380 Class‑B‑Stammaktien (gemeinsam mit seiner Ehefrau) und Aktienoptionen im Gesamtumfang von 137.881 Aktien aus fünf Zuteilungen, die in den Jahren 2021–2025 ausübbar sind, mit Ausübungspreisen zwischen $1.00 und $21.16. Die Aktien und Optionen wurden im Zusammenhang mit der Unternehmenszusammenführung mit Cyclo Therapeutics am 25. März 2025 erhalten oder umgewandelt.